Evaluation of Electrical Impedance Tomography for the Diagnosis of Chronic Rejection in Lung Transplants Recipients
NCT ID: NCT02863835
Last Updated: 2018-05-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2016-04-30
2017-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bronchoscopy and Electric Impedance Tomography (EIT) Pilot Study
NCT01294813
Electrical Impedance Tomography (EIT) Monitoring in Adults With ALI or ARDS
NCT01272882
Electrical Impedance Tomography of Lung in Child and Young Age
NCT02290535
Research on the Application of Electrical Impedance Tomography in Bronchial Challenge Testing
NCT06502405
Pulmonary Function Assessment and Evaluation Using Self-administrable and Portable Electrical Impedance Tomography
NCT05346081
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Currently, Forced Expiratory Volume at 1 second (FEV1) measurement is the gold standard to assess BOS severity. This test is non invasive and easily performed at bedside. Thus, it only gives a broad idea of the regional consequences of BOS as may be influenced by large airway obstructions. Chest computed tomography (CT) gives more detailed imaging of the regional consequences of BOS but is time-consuming and expose patients to radiations. Others imaging techniques such as ventilation/perfusion scintigraphy have been studied but cannot be performed at bedside.
As to date there is no curative treatment for BOS, preventive treatments such as long term azithromycin, bronchodilators, inhaled steroids or plasmapheresis have to be started at early stage of the disease to improve outcomes for the recipients Electrical impedance tomography (EIT) is a new technology that involves wearing a belt of sensors around the chest that provides information on how well the lungs are being filled with air by the ventilator. It allows the assessment of these differences, which previously required the use of invasive equipment to obtain. Information is gained by repeatedly injecting small alternating electric currents (usually 5 mA) at high frequency of 50 - 80 kHz through a system of skin electrodes (usually 16) applied circumferentially around the thorax in a single plane between the 4th and 6th intercostal space. While an adjacent pair of electrodes 'injects' the current ('adjacent drive configuration'), all the remaining adjacent passive electrode pairs measure the differences in electric potential. A resistivity (impedance) image is reconstructed from this data by a mathematical algorithm using a two dimensional model and a simplified shape to represent the thoracic cross-section.
The resulting image possesses a high temporal and functional resolution making it possible to monitor dynamic physiological phenomena (e.g. delay in regional inflation or recruitment) on a breath by breath basis. It is important to realize that the EIT images are based on image reconstruction techniques that require at least one measurement on a well-defined reference state. All quantitative data are related to this reference and can only indirectly quantify (relative) changes in local lung impedance (but not absolute).
EIT can be used in mechanically ventilated patients to assess recruitment and to optimise ventilator settings to reduce risk of iatrogenic ventilator associated lung injury. To date, EIT has never been used in lung transplant recipients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention 1
A 1:1 randomisation will be performed to decide the order of the administration of salbutamol and CPAP. All participants will receive both interventions in a cross-over fashion. Salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure.
Each participant will then have continuous assessment of the following whilst self venting:
* Spirometry - FEV1, FVC, MVV
* Muscle strength measurements: MIP, MEP, SNIP
* Borg scale, mMRC, Visual Analogue Scale for breathlessness
* Electrical impedance tomography
* EMGpara
* Transcutaneous measurement of CO2 and 02 level
* End-tidal CO2 monitoring
* Pneumotachography
EIT
All participants will have continuous monitoring of EIT whilst self venting
Salbutamol nebulisation and with CPAP
All participants will have continuous monitoring - salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure during this time.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EIT
All participants will have continuous monitoring of EIT whilst self venting
Salbutamol nebulisation and with CPAP
All participants will have continuous monitoring - salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure during this time.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Time from lung transplantation \> 6 months
* A chest CT scan (HRCT) performed as part of their standard care in the last 3 months
* A bronchoscopy with BAL and Biopsies performed as part of their standard care in the last 3 months
* For group with CLAD: a drop in lung function assessed on FEV1 or FVC
* For group without CLAD: an unchanged lung function
Exclusion Criteria
* Body mass index \> 40kg/m2
* Significant physical or psychiatric comorbidity that would prevent compliance with trial protocol
* Allergy to salbutamol
* Patient with intra-bronchial or intra-tracheal metallic stent
* Evidence of acute infection or acute cellular rejection.
In addition 10 healthy volunteers will be recruited
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ADIR Association
OTHER
Guy's and St Thomas' NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nick Hart
Role: STUDY_CHAIR
Guy's and St Thomas' NHS Foundation Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guys and St Thomas NHS Foundation
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16/LO/0198
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.